Sustained responses after anti-CD38 treatment with daratumumab in two patients with refractory systemic lupus

Tobias Alexander1,2, Lennard Ostendorf2,3, Robert Biesen4

  • 1Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany tobias.alexander@charite.de.

Abstract

No abstract available in PubMed .

Related Concept Videos